Abstract 29P
Background
Colorectal cancer (CRC) is one of the most common cancers worldwide. In particular, the yearly mortality emphasizes the limited spectrum of treatment possibilities. The tumor microenvironment with its relevant influence on malignant tumor initiation, progression and chemoresistance represents a promising target for cancer therapeutics. Especially cancer-associated fibroblasts (CAFs) are of importance in carcinogenesis as they are involved in tumorigenesis, metastasis, inflammatory responses, and extracellular matrix changes. Based on preliminary data, we found upregulated expression of INHBA, a gene encoding for the βA subunit of the TGFβ superfamily members Activin A, Activin AB and Inhibin A, in the stromal compartment of human CRC. Therefore, we wanted to investigate the autocrine and paracrine functional consequences of CAF-secreted Activin A in CRC.
Methods
We knocked down INHBA in primary patient-derived CAFs and used in vitro 3D collagen gel assays, flow cytometry, immunofluorescence, secretome analysis and Western blotting to check the autocrine effects of Activin A on CAFs. Regarding the paracrine impact on tumor cells and immune cells, we employed 3D co- and triple-culture collagen gel assays to determine the impact of CAF-derived Activin A. Here, we focused on proliferation, apoptosis and invasion levels of tumor cells as well as on monocyte differentiation, myeloid cell plasticity and T-cell activation.
Results
Our data demonstrate that CAFs expressing INHBA show a pro-proliferative, pro-motile and pro-contractile phenotype. Furthermore, the secretome and plasticity of CAFs were notably modified by the INHBA knockdown. Additionally, CAF-derived Activin A seems to influence various aspects of tumor progression and the plasticity of immune cells.
Conclusions
Together, our results indicate key functions of CAF-derived Activin A in CRC progression suggesting a potential novel therapeutic target.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Austrian Academy of Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09